Suppr超能文献

[近期抗高血压药物干预研究及其对指南的影响]

[Recent intervention studies with antihypertensive drugs and their influence on guidelines].

作者信息

Rahn Karl-Heinz

机构信息

Medizinische Klinik und Poliklinik D, Universitätsklinikum, Muenster.

出版信息

Med Klin (Munich). 2003 Dec 15;98(12):771-5. doi: 10.1007/s00063-003-1323-4.

Abstract

Antihypertensive therapy improves the prognosis of essential hypertension. Therapy reduces mortality and decreases the incidence of myocardial infarction, sudden cardiac death and stroke. Target blood pressure in patients with essential hypertension are levels < or = 140/90 mmHg. In patients with essential hypertension and concomitant diabetes mellitus type 2, blood pressure should be lowered to < or = 130/80 mmHg. Diuretics, beta-blockers, calcium antagonists, angiotensin-converting enyzme (ACE) inhibitors, and angiotensin I (AT(1)) antagonists may nowadays be regarded as drugs of first choice in the treatment of essential hypertension. The Joint National Committee in the USA recommends to start treatment with a thiazide diuretic. A Guidelines Committee of European Society of Hypertension-European Society of Cardiology considers the Endgroups of drugs mentioned above to be equally suitable for the initiation and maintenance of antihypertensive therapy. Both groups of experts agree that in the majority of patients with essential hypertension, a combination of two or more drugs is required to reach target blood pressure. Both groups of experts emphasize that the main benefits of antihypertensive therapy are due to decreasing blood pressure per se.

摘要

抗高血压治疗可改善原发性高血压的预后。治疗可降低死亡率,并减少心肌梗死、心源性猝死和中风的发生率。原发性高血压患者的目标血压水平为≤140/90 mmHg。对于合并2型糖尿病的原发性高血压患者,血压应降至≤130/80 mmHg。利尿剂、β受体阻滞剂、钙拮抗剂、血管紧张素转换酶(ACE)抑制剂和血管紧张素I(AT(1))拮抗剂如今可被视为治疗原发性高血压的首选药物。美国国家联合委员会建议开始使用噻嗪类利尿剂进行治疗。欧洲高血压学会-欧洲心脏病学会指南委员会认为上述药物类别同样适用于抗高血压治疗的起始和维持。两组专家均同意,大多数原发性高血压患者需要联合使用两种或更多药物才能达到目标血压。两组专家都强调,抗高血压治疗的主要益处在于血压本身的降低。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验